STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

JAZZ insider sale notice: $417,872 proposed NASDAQ sale

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Jazz Pharmaceuticals filed a Form 144 reporting a proposed sale of 3,731 shares of common stock with an aggregate market value of $417,872. The shares represent restricted stock that vested on 08/07/2025 and were acquired as compensation. The filer intends to sell the shares on or about 08/08/2025 on NASDAQ through ETRADE FINANCIAL CORPORATION. The company shows 60,658,809 shares outstanding and reports Nothing to Report for securities sold in the past three months. The notice includes the standard representation that the seller is unaware of any undisclosed material adverse information about the issuer.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine sale of vested restricted stock; transaction size is immaterial to capitalization and likely neutral for investors.

The filing documents a proposed open-market sale of 3,731 common shares valued at $417,872, acquired the day before by restricted stock vesting. Relative to 60,658,809 shares outstanding, this amount is de minimis, so the direct impact on supply, market float, and share price is likely negligible. The use of a retail broker (ETRADE FINANCIAL CORPORATION) and the absence of other sales in the prior three months suggest this is a one-off disposition tied to compensation rather than a broader insider liquidity event.

TL;DR: Filing follows standard Rule 144 procedures; disclosure and seller representations are present and complete for the information provided.

The notice specifies acquisition by restricted stock vesting and lists payment as compensation, which clarifies the economic basis of the shares offered for sale. The form includes the required representation that the seller is not aware of undisclosed material adverse information. No other sales in the last three months are reported, which simplifies aggregation considerations under Rule 144. Based only on stated facts, the filing appears procedurally compliant and non-material to governance or capital structure.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Jazz Pharmaceuticals Plc

NASDAQ:JAZZ

JAZZ Rankings

JAZZ Latest News

JAZZ Latest SEC Filings

JAZZ Stock Data

10.02B
58.92M
3.11%
105.97%
9.42%
Biotechnology
Pharmaceutical Preparations
Link
Ireland
DUBLIN